arrow
M

Matthew Collin

newcastle university
H指数:57
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

MEK抑制在Erdheim–Chester疾病中实现强效且持久的应答

2026-10-070
OAAI
Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia.

氟达拉滨-曲奥硫嘌呤与氟达拉滨-美法仑预处理方案在成人急性淋巴细胞白血病中的比较。

2026-01-010
OAAI
A European study on blood mutation monitoring in children with BRAFV600E-positive Langerhans Cell Histiocytosis

一项关于BRAFV600E阳性朗格汉斯细胞组织细胞增多症儿童血突变监测的欧洲研究

2026-01-010
OA
Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts

健康与疾病中的组织驻留髓系和组织细胞:新兴概念

2025-09-120
PREAI
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

达鲁atumumab治疗造血干细胞移植后纯红细胞再生障碍:EBMT移植并发症工作组的研究与实践考量

2025-06-040
OAAI
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT

比较冷冻保存与非冷冻保存的外周血造血干细胞在多发性骨髓瘤自体移植中的应用:EBMT慢性恶性疾病工作组的研究

2025-03-070
PRE
In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

在首次缓解期接受异基因移植的AML患者中,DNMT3A突变根据核型、NPM1和FLT3-ITD突变状态对移植后结局产生差异性影响——来自EBMT-ALWP

BLOOD
IF23.1
2024-11-050
PRE
Dose De-Escalation of Alemtuzumab in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation: A Single Centre Retrospective Study

阿伦单抗剂量降级在匹配无关供者造血干细胞移植中的应用:一项单中心回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
2024-06-010
OA
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures

朗格汉斯细胞组织细胞增生症: NACHO关于理性治疗道路上的进展,混乱和机会的更新

CANCER
IF5.1
2024-04-301
PRE
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT

VEXAS综合征的异基因造血细胞移植: EBMT的多中心研究结果

2024-03-1516
OAAI
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2024-03-070
OAAI
Graft-versus-Host Disease Prophylaxis with PostTransplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

在接受来自无关或不匹配的相关供体的异基因造血细胞移植的慢性粒细胞白血病患者中,移植后环磷酰胺预防移植物抗宿主病: 来自EBMT慢性恶性肿瘤工作组 (cmwp-ebmt) 的比较研究

2024-01-011
OAAI
Genome-Wide Association Study Identifies the First Germline Genetic Variant Associated With Erdheim-Chester Disease

全基因组关联研究确定了与erdheim-chester病相关的首个种系遗传变异

2023-11-073
OAAI
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

CD19 CAR T细胞治疗大b细胞淋巴瘤后的器官并发症: 来自EBMT移植并发症和淋巴瘤工作组的回顾性研究

2023-09-272
OAAI